Orchestra BioMed Holdings (OBIO) Notes Payables (2021 - 2022)
Orchestra BioMed Holdings' (OBIO) quarterly Notes Payables came in at $2.1 million in Q4 2022, up 1292.67% year-on-year from $150000.0 in Q4 2021, and up 1292.67% on a QoQ basis from $150000.0 in Q4 2021.
Orchestra BioMed Holdings (OBIO) Notes Payables (2021 - 2022) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 2 years of Notes Payables data on file, last reported at $2.1 million in Q4 2022.
- On a quarterly basis, Notes Payables rose 1292.67% year-over-year to $2.1 million in Q4 2022; TTM through Dec 2022 was $2.1 million, a 1292.67% increase from a year earlier, with the FY2022 full-year figure at $2.1 million, up 1292.67% from the prior year.
- Notes Payables for Q4 2022 stood at $2.1 million, up from $150000.0 in the prior quarter.
- Over the last five years, Notes Payables for OBIO reached as high as $2.1 million in Q4 2022 and fell as low as $150000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Orchestra BioMed Holdings | 240.54 Mn | 146.14 Mn | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.09 Mn |
| Dec 31, 2021 | 150,000.00 |